Technology Prognosis

tracking technologies before you have to make a decision

Ruzurgi (Amifampridine) for Pediatric Lambert-Eaton Myasthenic Syndrome

May 8, 2019

Ruzurgi (amifampridine, base form) is an oral drug intended for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to < 17 years. Ruzurgi is a voltage-gated potassium channel inhibitor that prolongs the depolarization of the pre-synaptic cell membrane, allowing for enhanced calcium influx into the neuron. This facilitates increased release of acetylcholine and improves neuromuscular transmission.